HC Wainwright upgraded shares of Eledon Pharmaceuticals (NASDAQ:ELDN - Free Report) to a buy rating in a report released on Wednesday, MarketBeat reports. The brokerage currently has $9.00 price objective on the stock. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.
Separately, Wall Street Zen downgraded shares of Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, June 6th.
View Our Latest Stock Analysis on ELDN
Eledon Pharmaceuticals Trading Down 2.2%
ELDN stock traded down $0.06 during midday trading on Wednesday, hitting $2.72. The company's stock had a trading volume of 244,846 shares, compared to its average volume of 274,584. Eledon Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $5.54. The company has a market cap of $162.87 million, a PE ratio of -1.30 and a beta of -0.17. The firm's 50-day moving average is $3.04 and its 200-day moving average is $3.69.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.20. Analysts expect that Eledon Pharmaceuticals will post -0.81 earnings per share for the current year.
Institutional Investors Weigh In On Eledon Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in shares of Eledon Pharmaceuticals by 418.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock valued at $33,000 after buying an additional 6,412 shares in the last quarter. CW Advisors LLC purchased a new position in shares of Eledon Pharmaceuticals during the 1st quarter valued at $34,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Eledon Pharmaceuticals during the 1st quarter valued at $41,000. Alpine Global Management LLC purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at $56,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at $66,000. Institutional investors own 56.77% of the company's stock.
Eledon Pharmaceuticals Company Profile
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
